- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02097186
Preconditioning Shields Against Vascular Events in Surgery (SAVES-F)
Preconditioning Shields Against Vascular Events in Surgery: A Multi-centre Feasibility Trial of Preconditioning Against Adverse Events in Major Vascular Surgery (Preconditioning-SAVES)
Study Overview
Status
Intervention / Treatment
Detailed Description
The demand for major vascular surgery is increasing [1]. Patients requiring procedures such as aortic aneurysm repair, carotid endarterectomy, lower limb surgical re-vascularisation and major lower limb amputation for end-stage vascular disease constitute a high-risk surgical cohort. Peri-operative complications such as myocardial infarction, cerebrovascular accident, renal failure and death are common [2,3]. Multiple potential mechanisms may result in these complications. For example, myocardial injury may result from systemic hypotension leading to reduced flow across a tight coronary artery stenosis or, alternatively, it may arise due to acute occlusion when an unstable plaque ruptures. Most strategies aimed at peri-operative risk reduction target a single potential mechanism. For example, beta-blockade may prevent myocardial injury due to overwork, but cannot prevent acute coronary occlusion. There is a requirement for a simple, effective intervention that protects tissues against injury via multiple different mechanisms. Remote ischemic preconditioning (RIPC) may be suitable.
Ischemic preconditioning is a phenomenon whereby a brief period of non-lethal ischemia in a tissue renders it resistant to the effects of a subsequent much longer ischaemic insult. It was first described in the canine heart [4]. Subsequent clinical trials showed that ischemic preconditioning reduced heart muscle damage following coronary artery bypass grafting [5] and liver dysfunction following hepatic resection [6]. Following cardiac surgery, it is associated with a reduction in critical care stay, arrhythmias and inotrope use [7]. However, ischemic preconditioning requires direct interference with the target tissues' blood supply, limiting its clinical utility. Further experimental work suggested that brief ischemia in one tissue, such as the kidneys, could confer protection on distant organs such as the heart [8]. A similar effect was observed after transient skeletal muscle ischemia [9-11]. This effect is referred to as 'preconditioning at a distance' or 'remote ischemic preconditioning' (RIPC).
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Mary Clarke Moloney, PhD
- Phone Number: 0035361482736
- Email: mary.clarkemoloney@hse.ie
Study Locations
-
-
-
Cork, Ireland, 000
- Not yet recruiting
- Cork University Hospital
-
Contact:
- Greg Fulton
- Email: greg.fulton@hse.ie
-
Principal Investigator:
- Greg Fulton
-
Sub-Investigator:
- Brian Manning
-
Dublin, Ireland, 000
- Recruiting
- Beaumont Hospital
-
Contact:
- Darragh Moneley
- Phone Number: 0035301809 3092
-
Principal Investigator:
- Darragh Moneley
-
Sub-Investigator:
- Austin Leahy
-
Dublin, Ireland, 000
- Recruiting
- St James's Hospital
-
Contact:
- Prakash Madhavan
- Email: pmadhavan@stjames.ie
-
Principal Investigator:
- Prakash Madhavan
-
Sub-Investigator:
- Zenia Martin
-
Sub-Investigator:
- Dermot Moore
-
Sub-Investigator:
- Sean O'Neill
-
Galway, Ireland, 00
- Recruiting
- University Hospital Galway
-
Contact:
- Stewart R Walsh
- Email: STEWARTREDMOND.WALSH@nuigalway.ie
-
Principal Investigator:
- Stewart R Walsh
-
Limerick, Ireland, 000
- Recruiting
- University Hospital Limerick (AKA MidWestern Regional Hospital)
-
Contact:
- Mary Clarke Moloney, PhD
- Phone Number: 0035361482736
- Email: mary.clarkemoloney@hse.ie
-
Sub-Investigator:
- Mary Clarke Moloney, PhD.
-
Principal Investigator:
- Eamon Kavanagh
-
Sub-Investigator:
- Paul Burke
-
Waterford, Ireland, 000
- Recruiting
- Waterford Regional Hospital
-
Contact:
- Simon Cross
-
Principal Investigator:
- Simon Cross
-
Sub-Investigator:
- Joseph Dowdall
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age greater than 18 years
- Patient willing to give full informed consent for participation
- Patients undergoing elective carotid endarterectomy or
- Patients undergoing open abdominal aortic aneurysm repair or
- Patients undergoing endovascular abdominal aneurysm repair or
- Patients undergoing surgical lower limb revascularisation (suprainguinal or infrainguinal)
Exclusion Criteria:
- Pregnancy
- Significant upper limb peripheral arterial disease
- Previous history of upper limb deep vein thrombosis
- Patients on glibenclamide or nicorandil (these medications may interfere with RIPC) Patients with an estimated pre-operative glomerular filtration rate < 30mls/min/1.73m2
- Patients with a known history of myocarditis, pericarditis or amyloidosis
- Patients with an estimated pre-operative glomerular filtration rate < 30mls/min/1.73m2.
- Patients with severe hepatic disease defined as an international normalised ratio >2 in the absence of systemic anticoagulation
- Patients with severe respiratory disease (for the trial, defined as patients requiring home oxygen therapy)
- Patients previously enrolled in the trial representing for a further procedure
- Patients with previous axillary surgery
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Remote ischaemic preconditioning
Remote ischaemic preconditioning will be performed in the same manner as several previous trials.
Immediately after induction of anaesthesia, a standard, CE-approved blood pressure cuff will be placed around one arm of the patient.
It will then be inflated to a pressure of 200mmHg for 5 minutes.
For patients with a systolic blood pressure >185mmHg, the cuff will be inflated to at least 15mmHg above the patient's systolic blood pressure.
The cuff will then be deflated and the arm allowed reperfuse for 5 minutes.
This will be repeated so that each patient receives a total of 4 ischaemia-reperfusion cycles.
In all other respects, the procedure and peri-operative care will follow the routine practices of the surgeons and anaesthetists involved.
|
Ischaemic preconditioning is a phenomenon whereby a brief period of non-lethal ischaemia in a tissue renders it resistant to the effects of a subsequent much longer ischaemic insult.
Remote ischaemic preconditioning works on the theory that brief ischaemia in one tissue could confer protection on distant organs.
Other Names:
|
No Intervention: Control to remote preconditioning group
Patients randomised to this group will receive routine pre-operative, peri-operative and post operative care.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Serum troponin levels
Time Frame: 3 days
|
The trial is intended to pragmatically evaluate the potential of RIPC to improve clinical outcomes among patients undergoing major vascular surgery in routine clinical practice.
For the pilot trial, a surrogate marker of efficacy will be used, namely serum troponin I levels.
The primary efficacy outcome will be a comparison of the proportion of patients in each arm of the trial who develop a serum troponin level in excess of the upper limit of normal in the first three post-operative days.
|
3 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Composite Major Adverse Clinical Events
Time Frame: 30 day
|
The primary endpoint for the trial will be Major Adverse Clinical Events.
This is a composite endpoint comprising any of: cardiovascular death, myocardial infarction, new onset arrhythmia requiring treatment, cardiac arrest, congestive cardiac failure, cerebrovascular accident, renal failure requiring renal replacement therapy, mesenteric ischaemia requiring intervention or biopsy proven ischaemic colitis, urgent cardiac revascularisation.
All participants will undergo a serum troponin levels and 12-lead electrocardiogram on the second post-operative day to screen for silent peri-operative myocardial infarction.
Trial ECGs and troponin levels will be interpreted by a blinded trial cardiologist.
|
30 day
|
Duration of post-operative hospital stay
Time Frame: 30 day
|
The duration of hospital stay and ITU stay have a major impact on health service resource utilisation, and are factors which can be influenced by surgery.
|
30 day
|
Duration of intensive care unit stay
Time Frame: 30 day
|
The duration of hospital stay and ITU stay have a major impact on health service resource utilisation, and are factors which can be influenced by surgery.
|
30 day
|
Unplanned critical care unit admission
Time Frame: 30 day
|
The duration of hospital stay and ITU stay have a major impact on health service resource utilisation, and are factors which can be influenced by surgery.
|
30 day
|
Acute kidney injury score in first three peri-operative days
Time Frame: 3 days
|
The Acute Kidney Injury Score will be calculated over the first three peri-operative days.
Creatinine will be measured daily as part of routine care.
Urine volumes will be calculated from the fluid balance charts maintained as part of usual care.
|
3 days
|
Post-operative complications
Time Frame: 30 day
|
Postoperative complications will be recorded and results from both groups compared.
|
30 day
|
Mortality
Time Frame: 1 year
|
Death within one year of surgery will be determined by contacting the patient's general practitioner.
|
1 year
|
Cardiac or cerebral event
Time Frame: 1 year
|
Major adverse cardiac or cerebral event (myocardial infarction, cardiac death, cerebrovascular accident) within 1 year of surgery will be determined by contacting the patient's general practitioner for details.
|
1 year
|
Acute upper limb ischaemia
Time Frame: 24 hours post-operatively
|
Acute upper limb ischaemia - This is defined as the development of ischaemia in the arm used for the preconditioning stimulus requiring systemic anti-coagulation, radiological intervention or surgical intervention.
The arm will be assessed at the end of surgery to identify if ischaemia is present.
|
24 hours post-operatively
|
Acute upper limb deep vein thrombosis
Time Frame: 10 days
|
Acute upper limb deep vein thrombosis - This is defined as the development of thrombus within the subclavian, axillary or brachial vein, which may develop up to 10 days post procedure, confirmed in duplex ultrasound and in the same arm as used for the RIPC stimulus.
|
10 days
|
Serial troponin I results
Time Frame: 3 days
|
A comparison of the area under the curve of serial troponin I
|
3 days
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Acceptability of RIPC to patients
Time Frame: 6 weeks
|
For patients, particularly those undergoing regional anaesthesia rather than general, the intervention may be burdensome and uncomfortable which may negatively impact upon likely adoption of this intervention into routine practice.In order to explore these potential issues, this feasibility trial will include a qualitative evaluation of acceptability to patients together with a qualitative evaluation of any perceived barriers to implementation.
This evaluation will take the form of a semi-structured phone interview.
|
6 weeks
|
Acceptability and barriers to implementation among healthcare professionals.
Time Frame: 24 months
|
Healthcare professionals at participating practices will be asked to complete a self-administered electronic questionnaire at the end of the study period.
The questionnaire will elicit data on profession and practice details, their perceived experience of trial involvement, and open-ended questions to elicit information regarding attitudes to trial involvement, willingness to recruit participants, difficulties that arose during the trial and potential barriers to further research or routine clinical use of the trial intervention.
|
24 months
|
Collaborators and Investigators
Investigators
- Principal Investigator: Stewart R Walsh, MCh FRCS, Mid Western Regional Hospital and University of Limerick
Publications and helpful links
General Publications
- Murry CE, Jennings RB, Reimer KA. Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. Circulation. 1986 Nov;74(5):1124-36. doi: 10.1161/01.cir.74.5.1124.
- Greenhalgh RM, Brown LC, Kwong GP, Powell JT, Thompson SG; EVAR trial participants. Comparison of endovascular aneurysm repair with open repair in patients with abdominal aortic aneurysm (EVAR trial 1), 30-day operative mortality results: randomised controlled trial. Lancet. 2004 Sep 4-10;364(9437):843-8. doi: 10.1016/S0140-6736(04)16979-1.
- Kharbanda RK, Mortensen UM, White PA, Kristiansen SB, Schmidt MR, Hoschtitzky JA, Vogel M, Sorensen K, Redington AN, MacAllister R. Transient limb ischemia induces remote ischemic preconditioning in vivo. Circulation. 2002 Dec 3;106(23):2881-3. doi: 10.1161/01.cir.0000043806.51912.9b.
- Anderson PL, Gelijns A, Moskowitz A, Arons R, Gupta L, Weinberg A, Faries PL, Nowygrod R, Kent KC. Understanding trends in inpatient surgical volume: vascular interventions, 1980-2000. J Vasc Surg. 2004 Jun;39(6):1200-8. doi: 10.1016/j.jvs.2004.02.039.
- Chambers BR, Donnan GA. Carotid endarterectomy for asymptomatic carotid stenosis. Cochrane Database Syst Rev. 2005 Oct 19;2005(4):CD001923. doi: 10.1002/14651858.CD001923.pub2.
- Jenkins DP, Pugsley WB, Alkhulaifi AM, Kemp M, Hooper J, Yellon DM. Ischaemic preconditioning reduces troponin T release in patients undergoing coronary artery bypass surgery. Heart. 1997 Apr;77(4):314-8. doi: 10.1136/hrt.77.4.314.
- Clavien PA, Selzner M, Rudiger HA, Graf R, Kadry Z, Rousson V, Jochum W. A prospective randomized study in 100 consecutive patients undergoing major liver resection with versus without ischemic preconditioning. Ann Surg. 2003 Dec;238(6):843-50; discussion 851-2. doi: 10.1097/01.sla.0000098620.27623.7d.
- Walsh SR, Tang TY, Kullar P, Jenkins DP, Dutka DP, Gaunt ME. Ischaemic preconditioning during cardiac surgery: systematic review and meta-analysis of perioperative outcomes in randomised clinical trials. Eur J Cardiothorac Surg. 2008 Nov;34(5):985-94. doi: 10.1016/j.ejcts.2008.07.062. Epub 2008 Sep 9.
- Przyklenk K, Bauer B, Ovize M, Kloner RA, Whittaker P. Regional ischemic 'preconditioning' protects remote virgin myocardium from subsequent sustained coronary occlusion. Circulation. 1993 Mar;87(3):893-9. doi: 10.1161/01.cir.87.3.893.
- Birnbaum Y, Hale SL, Kloner RA. Ischemic preconditioning at a distance: reduction of myocardial infarct size by partial reduction of blood supply combined with rapid stimulation of the gastrocnemius muscle in the rabbit. Circulation. 1997 Sep 2;96(5):1641-6. doi: 10.1161/01.cir.96.5.1641.
- Oxman T, Arad M, Klein R, Avazov N, Rabinowitz B. Limb ischemia preconditions the heart against reperfusion tachyarrhythmia. Am J Physiol. 1997 Oct;273(4):H1707-12. doi: 10.1152/ajpheart.1997.273.4.H1707.
- Healy D, Clarke-Moloney M, Gaughan B, O'Daly S, Hausenloy D, Sharif F, Newell J, O'Donnell M, Grace P, Forbes JF, Cullen W, Kavanagh E, Burke P, Cross S, Dowdall J, McMonagle M, Fulton G, Manning BJ, Kheirelseid EA, Leahy A, Moneley D, Naughton P, Boyle E, McHugh S, Madhaven P, O'Neill S, Martin Z, Courtney D, Tubassam M, Sultan S, McCartan D, Medani M, Walsh S. Preconditioning Shields Against Vascular Events in Surgery (SAVES), a multicentre feasibility trial of preconditioning against adverse events in major vascular surgery: study protocol for a randomised control trial. Trials. 2015 Apr 23;16:185. doi: 10.1186/s13063-015-0678-1.
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Pathologic Processes
- Cardiovascular Diseases
- Vascular Diseases
- Cerebrovascular Disorders
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Arteriosclerosis
- Arterial Occlusive Diseases
- Aortic Diseases
- Ischemia
- Carotid Artery Diseases
- Atherosclerosis
- Aneurysm
- Aortic Aneurysm
- Aortic Aneurysm, Abdominal
Other Study ID Numbers
- SAVES-F
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Carotid Atherosclerosis
-
Universidade Camilo Castelo BrancoCompletedSubclinical Carotid Atherosclerosis
-
Silk Road MedicalCompletedCarotid Artery Plaque | Carotid Stenosis | Carotid Artery Diseases | Carotid Atherosclerosis | Carotid DiseaseUnited States, Spain
-
University of PennsylvaniaMerck Sharp & Dohme LLC; The Dana Foundation; Kos PharmaceuticalsCompletedEstablished Carotid Atherosclerosis
-
Sohag UniversityRecruitingCarotid Artery Plaque | Carotid Stenosis | Carotid AtherosclerosisEgypt
-
Linkoeping UniversityRegion Östergötland; Region Jönköping County; FORSS, Forskningsrådet i Sydöstra...CompletedCarotid Artery Plaque | Carotid Stenosis | Carotid Atherosclerosis
-
Silk Road MedicalTechnical University of Munich; University Ghent; Complejo Hospitalario ToledoCompletedThe ENROUTE Transcarotid Neuroprotection System (ENROUTE Transcarotid NPS) DW-MRI Study (DW-MRI OUS)Carotid Artery Plaque | Carotid Stenosis | Carotid Artery Diseases | Carotid AtherosclerosisBelgium, Spain, Germany
-
Abbott Medical DevicesCompletedCarotid Atherosclerosis | Carotid Artery Disease
-
Azienda Ospedaliero-Universitaria di ModenaCompletedStroke | Carotid Artery Plaque | Carotid Stenosis | Carotid Artery Diseases | Carotid Atherosclerosis | TCDItaly
-
Peking UniversityCompletedCarotid Atherosclerosis | Carotid Intimal Medial Thickness 1China
-
Washington University School of MedicineNational Heart, Lung, and Blood Institute (NHLBI); Cedars-Sinai Medical Center and other collaboratorsRecruitingCarotid Atherosclerosis | Asymptomatic Carotid Artery Stenosis | Carotid Artery AtheromaUnited States
Clinical Trials on Remote ischaemic preconditioning
-
University of NottinghamRecruitingVascular Diseases | HypertensionUnited Kingdom
-
Western University, CanadaAcademic Medical Organization of Southwestern OntarioTerminatedCardiovascular Diseases | Hemodialysis
-
University College London HospitalsCompletedCoronary Heart DiseaseUnited Kingdom
-
University College, LondonUniversity College London HospitalsUnknownCardiotoxicityUnited Kingdom
-
First Affiliated Hospital Xi'an Jiaotong UniversityNot yet recruitingIschemic PreconditioningChina
-
Mid Western Regional Hospital, IrelandCompletedContrast Induced Nephropathy | Remote Ischaemic PreconditioningIreland
-
Sun Yat-sen UniversityGuangzhou First People's HospitalCompletedHeart Valve DiseasesChina
-
University College, LondonUniversity College London Hospitals; National Hospital for Neurology and Neurosurgery...Unknown
-
NHS National Waiting Times Centre BoardUniversity of Glasgow; Chief Scientist Office of the Scottish Government; Chest...CompletedCoronary Disease | Ischemic PreconditioningUnited Kingdom
-
The University of Hong KongCompleted